[Management of patients with chronic renal failure during surgical correction of cardiovascular disease].

End-stage of chronic renal failure (CRF) is frequently associated with cardiac and vascular comorbidities requiring cardiosurgical interventions. Over 9 years, from 2000 to 2009, the A. N. Bakulev Research Center of Cardiovascular Surgery, Russian Academy of Medical Sciences, delivered cardiosurgical care to 16 patients aged 20 to 74 years with end-stage CRF. The duration of programmed hemodialysis was 1 to 102 months. The preoperative patient preparation protocol comprised correction of anemia, hypoproteinemia, hypertension, and water-electrolyte and acid-base balances. Five patients underwent endovascular myocardial revascularization; open heart surgery was performed in one patient. Interventions under extracorporeal circulation were made in 10 other patients. Ultrafiltration was intraoperatively carried out. On-line hemodiafiltration was performed following coronary artery stenting. After open operations, renal replacement therapy (first hemodiafiltration, then hemodialysis) as daily sessions was initiated on day 2 and, when the patients were transferred to intensive care units, it was performed by the programmed hemodialysis protocol. There were no fatal outcomes at the follow-up. The key aspects of treatment success achievement and improved quality of life in patients on programmed hemodialysis are the detection of cardiovascular diseases requiring surgery, the timely referral of the patients to a cardiosurgical hospital, the meticulous pre- and perioperative management (correction of anemia, hypoproteinemia, water-electrolyte balance, use of ultrafiltration and the adequate rate of perfusion at the stage of extracorporeal circulation, and daily renal replacement therapy in the postoperative period), and continuity in the work of all specialists.

[Selective hemoperfusion in gram-negative severe sepsis of patients after cardiac surgery: a prospective randomized study].

Early in the new millennium, sepsis remains one of the most urgent problems of modern reanimatology. Endotoxin, a component of the cell wall of gram-negative bacteria is of paramount importance in the pathogenesis of sepsis. Complex intensive care for severe sepsis involves selective endotoxin hemoperfusion with Polymyxin B and Alteco LPS adsorber, which has been performed in 2 patients. This study will enable specialists to formulate their opinion as to whether it is expedient to incorporate selective endotoxin hemoperfusion into complex intensive care for severe sepsis.

[The first experience in using selective sorbents in complex intensive care of patients with infectious and septic complications after cardiac surgery].

Early in the new millennium, sepsis remains one of the most urgent problems of modern medicine as before in view of a steady tendency for a rise of morbidity rates and for stably high mortality rates in patients (from 30 to 70%). The endotoxin lipopolysaccharide (LPS) of the cell wall of gram-negative bacteria plays the most important role in the pathogenesis of sepsis. This paper assesses the first experience in using endotoxin-selective sorption technologies within complex intensive care of critically ill patients with infectious and septic complications after cardiac surgery. Group 1 comprised 6 patients undergoing Alteco LPS adsorption procedures. Group 2 included 5 patients having hemoperfusion using Polymixin B-based Toraymyxin columns. The authors'first experience in clinically using LPS adsorption suggests that it is absolutely expedient to include extracorporeal selective hemoperfusion into the complex intensive care for infectious and septic complications in patients after operations on the heart and vessels.